Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats

Cancer Prevention Research

Volumn 6, Issue 12, 2013, Pages 1251-1261

  Janakiram, Naveena B ^a   Mohammed, Altaf ^a   Zhang, Yuting ^a   Brewer, Misty ^a   Bryant, Taylor ^a   Lightfoot, Stan ^b   Steele, Vernon E ^c   Rao, Chinthalapally V ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BETA CATENIN; BEXAROTENE; CYCLIN D1; CYCLINE; PROTEIN P21; RALOXIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ARTIFICIAL DIET; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; COLON ADENOCARCINOMA; COLON ADENOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; AZOXYMETHANE; BLOTTING, WESTERN; COLONIC NEOPLASMS; DRUG THERAPY, COMBINATION; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; RALOXIFENE; RATS; RATS, INBRED F344; REAL-TIME POLYMERASE CHAIN REACTION; RETINOID X RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAHYDRONAPHTHALENES; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84890514017     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0249     Document Type: Article

References (49)

1. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001;61:632-40.
2. Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol Rep 2005;14:17-21.
3. Janakiram NB, Steele VE, Rao CV. Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res 2009;2:52-9.
4. Thomas ML, Xu X, Norfleet AM, Watson CS. The presence of functional estrogen receptors in intestinal epithelial cells. Endocrinology 1993; 132:426-30.
5. Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor β is expressed in human colorectal adenocarcinoma. Hum Pathol 2001; 32:940-4.
6. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991-1004.
7. Hulley S, Furberg C, Barrett-Connor E, Grady D, Haskell W, Knopp R, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
8. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 2008;68:329-37.
9. Clendenen TV, Koenig KL, Shore RE, Levitz M, Arslan AA, Zeleniuch-Jacquotte A. Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:275-81.
10. Wu H, Xu L, Chen J, Hu J, Yu S, Hu G, et al. Association of estrogen receptor beta variants and serum levels of estradiol with risk of colorectal cancer: a case control study. BMC Cancer 2012;12:27.
11. Simon MS, Chlebowski RT, Wactawski-Wende J, Johnson KC, Muskovitz A, Kato I, et al. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol 2012;30:3983-90.
12. Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissuespecific agonist and antagonist actions. Steroid 2002;67: 15 -24.
13. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123- 5.
14. Janakiram NB, Cooma I, Mohammed A, Steele VE, Rao CV. B-Ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-A in human colon cancer cells. Mol Cancer Ther 2008;7:181-9.
15. Janakiram NB, Mohammed A, Qian L, Choi C-I, Steele VE, Rao CV. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of ApcMin/+Mice. Neoplasia 2012;14:159-68.
16. Segars JH, Marks MS, Hirschfeld S, Driggers PH, Martinez E, Grippo JF, et al. Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. Mol Cell Biol 1993;13:2258-68.
17. Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 1002681. Clin Cancer Res 2002; 8:3270-5.
18. Price RH Jr, Lorenzon N, Handa RJ. Differential expression of estrogen receptor beta splice variants in rat brain: identification and characterization of a novel variant missing exon 4. Mol Brain Res 2000;80:260 -8.
19. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999;261:521 -7.
20. Xie L-Q, Yu J-P, Luo H-S. Expression of estrogen receptor b in human colorectal cancer. World J Gastroenterol 2004;10:214-7.
21. Konstantinopoulos PA, Kominea AV, Oros G, Sykiotisa GP, Andricopoulosd P, Varakisb I, et al. Oestrogen receptor b (ERb) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39:1251-8.
22. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
23. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008;17:2609-18.
24. Saleiro D, Murillo G, Benya RV, Bissonnette M, Hart J, Mehta RG. Estrogen receptor-beta protects against colitis-associated neoplasia in mice. Int J Cancer 2012;131:2553-61.
25. Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. Estrogen receptor β deficiency enhances small intestinal tumorigenesis in Apc- Min/+mice. Int J Cancer 2008;123:303-11.
26. Giroux V, Bernatchez G, Carrier JC. Chemopreventive effect of ERβ-selective agonist on intestinal tumorigenesis in Apc(Min/+) mice. Mol Carcinog 2011;50:359-69.
27. Heijmans J, Wielenga MC, Rosekrans SL, van Lidth de Jeude JF, Roelofs J, Groothuis P, et al. Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer. Gut 2013 Feb 13. [Epub ahead of print].
28. Janakiram NB, Mohammed A, Qian L, Venkateshwar M, Reddy MP, Steele VE, et al. Chemopreventive effects of selective estrogen receptor modulator (SERM) raloxifene on intestinal neoplasia of APCMin/+ mice. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; 2011;71(8 Suppl). Abstract nr 831.
29. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009;9:51-60.
30. Martínez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009;136: 832- 41.
31. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
32. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355: 125 - 37.
33. Walsh JM, Cheung AM, Yang D, Litwack S, Grady D. J. Raloxifene and colorectal cancer. Womens Health (Larchmt) 2005;14: 299 - 305.
34. Wang Y, Zhang Z, Yao R, Jia D, Wang D, Lubet RA, et al. Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 2006;25:1320-9.
35. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 2006;13:51-68.
36. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 2002;11:467-74.
37. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996;56: 5566 - 70.
38. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-80.
39. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998;58:479-84.
40. Cohen SM. Role of cell proliferation in regenerative and neoplastic disease. Toxicol Lett 1995;82 -83:15-21.
41. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991;65:1097-8.
42. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-4.
43. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A, Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 2006;13:51-68.
44. Kumru S, Yildiz FM, Godekmerdan A, Kutlu S, Yilmaz B, Gurates B. Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial. Arch Gynecol Obstet 2008; 277:489-93.
45. Budgin JB, Richardson SK, Newton SB, Wysocka M, Zaki MH, Benoit B, et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005;141:315-20.
46. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor- and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001;88:825-8.
47. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, et al. Raloxifene modulates interleukin-6 and tumor necrosis factoralpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004;89:6079-99.
48. β1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007;18:148-53.
49. Yasui T, Uemura H, Hyodo S, Yamada M, Yamamoto S, Maegawa M, et al. Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women. Atherosclerosis 2009;204:471-5.